BioMark Diagnostics Inc.
BUX
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -8.43% | -6.45% | -1.28% | 1.53% | 4.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.43% | -6.45% | -1.28% | 1.53% | 4.22% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -8.43% | -6.45% | -1.28% | 1.53% | 4.22% |
| SG&A Expenses | 31.38% | 25.49% | 13.41% | -6.25% | -23.50% |
| Depreciation & Amortization | -2.37% | -31.22% | -18.76% | -12.06% | -0.21% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.01% | 6.26% | 15.00% | -0.17% | -7.89% |
| Operating Income | -16.17% | -7.44% | -16.46% | 0.33% | 8.92% |
| Income Before Tax | -31.39% | -21.76% | -28.02% | 12.75% | 24.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.39% | -21.76% | -28.02% | 12.75% | 24.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.39% | -21.76% | -28.02% | 12.75% | 24.10% |
| EBIT | -16.17% | -7.44% | -16.46% | 0.33% | 8.92% |
| EBITDA | -16.23% | -7.42% | -16.55% | 0.35% | 8.99% |
| EPS Basic | 0.00% | 3.68% | -19.85% | 16.87% | 26.04% |
| Normalized Basic EPS | 0.00% | 3.53% | -20.00% | 16.50% | 25.71% |
| EPS Diluted | 0.00% | 3.68% | -19.85% | 16.87% | 26.04% |
| Normalized Diluted EPS | 0.00% | 3.53% | -20.00% | 16.50% | 25.71% |
| Average Basic Shares Outstanding | 247.75% | 244.38% | 6.06% | 3.77% | 1.64% |
| Average Diluted Shares Outstanding | 247.75% | 244.38% | 6.06% | 3.77% | 1.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |